Moukengue Brice, Lallier Morgane, Marchandet Louise, Baud'huin Marc, Verrecchia Franck, Ory Benjamin, Lamoureux Francois
Nantes Université, INSERM UMR1307, CNRS UMR6075, Université d'Angers, CRCI2NA, Team 9, CHILD, F-44000 Nantes, France.
CHU de Nantes, F-44300 Nantes, France.
Cancers (Basel). 2022 Jul 19;14(14):3503. doi: 10.3390/cancers14143503.
Osteosarcoma (OS) is the most frequent primary bone tumor, mainly affecting children and young adults. Despite therapeutic advances, the 5-year survival rate is 70% but drastically decreases to 20-30% for poor responders to therapies or for patients with metastasis. No real evolution of the survival rates has been observed for four decades, explained by poor knowledge of the origin, difficulties related to diagnosis and the lack of targeted therapies for this pediatric tumor. This review will describe a non-exhaustive overview of osteosarcoma disease from a clinical and biological point of view, describing the origin, diagnosis and therapies.
骨肉瘤(OS)是最常见的原发性骨肿瘤,主要影响儿童和年轻人。尽管治疗取得了进展,但5年生存率为70%,但对于治疗反应不佳或有转移的患者,这一比例会急剧降至20%-30%。四十年来,生存率没有真正的提高,原因是对其起源了解不足、诊断困难以及缺乏针对这种儿科肿瘤的靶向治疗。本综述将从临床和生物学角度对骨肉瘤疾病进行非详尽的概述,描述其起源、诊断和治疗方法。